Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will ...

Over the weekend, a Texas aerospace company made history with the first successful landing on the moon by a private firm.

Yahoo Finance host Josh Lipton tracks the day's biggest stocks in this Market Minute. AbbVie (ABBV) announced a licensing ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

A rebound in stocks sputtered as data showed US manufacturing approached stagnation amid a jump in prices. The S&P 500 erased gains, with a slide in megacaps like Nvidia Corp. and Microsoft Corp. also ...

In February 2025, stock markets fell on average. The S&P 500 (SPY) fell by 1.27%, due mostly to a decline in technology stocks. Investors reallocated their holdings into the drug sector. AbbVie (ABBV) ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

A rebound in stocks wavered as bonds climbed after data showed US manufacturing activity approached stagnation while prices jumped.

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...